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1 
MOLECULAR STUDIES AND CLINICAL EVALUATION OF 
CONGENITAL GLAUCOMA 
 
INTRODUCTION 
Glaucoma is defined as a disturbance to the structural or functional integrity of the optic 
nerve which can be arrested or diminished by adequately lowering IOP1. It can also be described 
as chronic progressive optic neuropathy with characteristic optic nerve head changes and 
corresponding field defects, with the only modifiable risk factor being elevated IOP2. In Greek, 
the word Glaucoma means ‘clouded’. 
Glaucomatous atrophy is characterized by progressive death of retinal ganglion cells 
which appears as excavation of the cup and is functionally apparent as sequential visual field 
deterioration in specific patterns. 
Primary Glaucomas are generally not associated with known ocular or systemic disorders 
leading to increased resistance to aqueous outflow; usually, they are bilateral and reflect genetic 
predispositions. However, Secondary Glaucomas are associated with ocular or systemic 
abnormalities responsible for elevated IOP; these are usually unilateral and acquired diseases. 
Congenital Glaucoma 
According to Sir Stewart Duke-Elder (1963): “Buphthalmos (hydrophthalmos) is the 
condition wherein developmental abnormalities offer an obstruction to the drainage of the intra-
ocular fluids so that the pressure of the eye is raised and a condition of Congenital Glaucoma 
results. The essential clinical feature of the anomaly is that the coats of the eye are of sufficient 
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plasticity to stretch under this increment of pressure with the results that the whole globe 
enlarges, producing an appearance which is said to resemble the eye of an ox”3. 
Shaffer and Weiss (1970) describes Primary Congenital Glaucoma as, “The most 
common hereditary Glaucoma of childhood, inherited as an autosomal recessive pattern, with a 
specific angle anomaly consisting of absence of angle recess with iris insertion directly into the 
trabecular surface. There are no other major abnormalities of development. Corneal enlargement, 
clouding, and tears in Descemet’s Membrane result from elevated intraocular pressure.”4 
Loss of retinal ganglion cells leading to irreversible blindness is caused by increased IOP, 
which is bilateral in 80% of cases. Over 80% of cases are diagnosed by the first year of life. Of 
this, the disease is diagnosed in 25% of the cases in the neonatal period, and in 60% of cases by 
the first six months. Primary Congenital Glaucoma is the most common type, and it accounts for 
55% of primary pediatric glaucoma. 
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HISTORICAL REVIEW 
              460–377 BC: Congenital enlargement of the eye was identified by Hippocrates, later by 
Celsus and Galen. The relationship between glaucoma and IOP was not known.  
              1744: Increased IOP associated with Congenital Glaucoma was described by Berger  
               1869: Buphthalmos which was classical within in a family was described by Von 
Muralt. However, it was believed to be caused by a primary intraocular inflammation according 
to both Von Muralt and Von Graefe.  
Precise anatomical dissections were performed and the etiopathology was found to be 
related to various malformations of the structures of the angle of the anterior chamber (AC) only 
in the late 1800s. Similar studies were done by von Hippel, Parsons, Siegrist, Reis and many 
others. 
Congenital Glaucomas were considered not treatable in the early 1900s. Anderson said, 
“the future of patients with Hydrophthalmia is dark” and “one seeks in vain for a best operation 
in the treatment of Hydrophthalmia”.5 Infantile Glaucoma had poor prognosis until Otto Barkan 
introduced Goniotomy6. He created an internal cleft in the trabecular tissue and incised it with a 
knife under visualization through a specialized glass contact lens. The operation remains 
unchanged, except for instrumental and microscopic development. 
Barkan (1949) described a fetal membrane persisting over the trabecular tissue. Worst 
(1966) confirmed this and named it Barkan’s Membrane. However the presence of such a glassy 
membrane was not evident by electron microscopic study. 
4 
Goniotomy remained the standard for Congenital Glaucoma until 1960, when Burian and 
Smith, on different occasions, described a new technique called “trabeculectomy ab externo”. 
Burian performed the first external trabeculectomy without the aid of an operating microscope, 
in March 19607. Redmond Smith described a new procedure called “nylon filament 
trabeculotomy”. Later, Harms (1969), Dannheim (1971) and McPherson (1973) modified the 
surgical technique of trabeculotomy ab externo. 
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TERMINOLOGY 
General Description 
1. Buphthalmos literally means Ox eye. It is described as any type of marked enlargement 
occurring as a result of Glaucoma since birth. 
2. Hydrophthalmos means increased fluid content which is present in a prominently 
enlarged eye due to Glaucoma in infancy8. Buphthalmos and Hydrophthalmia are 
outdated terms. 
Terms describing developmental pattern: 
 Developmental Glaucoma: it is a condition that is related to anomalous development of 
the eye at birth, which includes primary congenital glaucoma and Secondary Glaucomas 
associated with ocular or systemic developmental anomalies. The terms Congenital Glaucoma 
and Developmental Glaucoma are synonymous. 
Primary Developmental Glaucoma: caused by the maldevelopment of the aqueous 
outflow system. Primary Congenital Glaucoma is a specific term which refers to eyes with an 
isolated maldevelopment of the trabecular meshwork, and where other developmental ocular 
anomalies or diseases that can raise intraocular pressure are absent. 
Secondary developmental glaucoma: Secondary Glaucoma in infants refers to Glaucoma 
due to acquired ocular diseases. It is caused by impedence in the aqueous outflow system due to 
defective development of any other part of the eye, such as, ectopia lentis, microspherophakia, 
pupillary block in a small eye, or as an anterior displacement of the lens-iris diaphragm in any 
other developmental posterior segment pathology. 
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Terms describing structural anomalies 
 1. Goniodysgenesis, maldevelopment of irido-corneal angle 
 2. Trabeculodysgenesis, maldevelopment of trabecular meshwork 
 3. Irido-dysgenesis, maldevelopment of iris, and 
 4. Corneodysgenesis: maldevelopment of cornea. 
They have varied mode of presentation. It could be present either as a single entity or in 
combination with other conditions. Trabeculodysgenesis alone is a pathognomonic feature of 
primary developmental glaucoma. 
Relating to age of onset 
                 Infantile Glaucoma is a term used in different contexts. Some use it to indicate 
Primary Congenital Glaucoma, while some use it to indicate any glaucoma occurring in the early 
years of life. Hence, its context should be specified or it should be avoided. Primary Infantile 
Glaucoma and Primary Congenital Glaucoma are synonymous. 
 Juvenile Glaucoma is a non-specific term that refers to any type of Glaucoma occurring 
after the age of 5 and up to the third and fourth decades. Juvenile Glaucoma associated with 
myopia with autosomal dominant inheritance has been linked to the short arm of the first human 
chromosome (1q), coding for the myocilin gene (MYOC) 1. 
  
 
 
7 
CLASSIFICATION 
SYNDROME CLASSIFICATION OF CONGENITAL GLAUCOMA 
I.  Primary glaucoma 
A. Congenital open-angle Glaucoma 
B. Juvenile Glaucoma (AD inheritance) 
C. Glaucoma presenting with systemic manifestations 
1.  Axenfeld-Rieger syndrome 
2. Chromosomal disorders 
3. Congenital rubella 
4. Fetal alcohol syndrome 
5. Mucopolysaccharidosis 
6. Neurofibromatosis 
7. Oculocerebrorenal (Lowe) syndrome 
8. Hepatocerebrorenal (Zellweger) syndrome 
9. Oculodermal vascular malformations 
a. Sturge-Weber syndrome 
b. Klippel-Trenaunay-Weber syndrome 
c. Oculodermal melanocytosis 
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d. Phakomatosis pigmentovascularis 
e. Cutis marmorata telangiectasia congenita 
10. Prader-Willi syndrome 
11. Rubenstein-Taybi (broad-thumb) syndrome 
12. Pierre Robin and Stickler syndromes 
13. Skeletal dysplastic syndromes 
a. Kniest syndrome 
b. Michel syndrome 
c. Oculodentodigital syndrome 
D. Glaucoma in other ocular pathological conditions 
1.  Aniridia 
2. Axenfeld-Rieger syndrome 
3. Congenital ectropion uveae 
4. Congenital hereditary endothelial dystrophy 
5. Microcornea syndromes 
6. Familial iris hypoplasia 
7. Peter’s syndrome 
8. Posterior polymorphous dystrophy 
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9. Sclerocornea 
II. Secondary glaucoma 
A. Glaucoma in ocular trauma 
B. Glaucoma associated with intraocular malignancies 
1.  Retinoblastoma 
2. Juvenile xanthogranuloma 
3. Leukemia 
4. Iris rhabdomyosarcoma 
C. Glaucoma in Uveitis 
D. Lens-induced Glaucoma 
1.  Subluxation – dislocation with pupillary block 
a. Marfan syndrome 
b. Homocystinuria 
2. Spherophakia with pupillary block 
a. Weill-Marchesani syndrome 
b. GEMSS syndrome  
E. Glaucoma following cataract surgery 
1.  Chronic open-angle (aphakic or pseudophakic) 
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2. Lens debris or uveitic blockade of trabeculum 
3. Pupillary blockade 
F. Glaucoma in Steroid responders 
G. Neovascular Glaucoma 
1.  Retinoblastoma 
2. Coats’ disease 
3. Medulloepithelioma 
4. Familial exudative vitreoretinopathy 
H. Secondary angle-closure Glaucoma 
1.  Retinopathy of prematurity 
2. Microphthalmos 
3. Nanophthalmos 
4. Retinoblastoma 
5. Persistent hyperplastic primary vitreous 
6. Congenital papillary–iris lens membrane 
7. Aniridia 
8. Iridoschisis 
9. Cornea plana 
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I.  Glaucoma associated with episcleral venous hypertension 
1.  Sturge-Weber syndrome 
2. Idiopathic or familial elevated episcleral venous pressure 
3. Orbital vascular malformations 
J. Glaucoma following infections in eye 
1.  Acute Toxoplasmosis 
2. Acute herpetic iritis 
3. AIDS related infections 
4. Congenital rubella 
DeLuise–Anderson (1983) classification of Congenital and Infantile Glaucoma9 
1. Primary Infantile Glaucoma (Congenital Glaucoma, trabeculo-dysgenesis) 
2. Secondary Infantile Glaucoma 
A. Associated with mesodermal neural crest dysgenesis 
1. Iridocorneotrabeculodysgenesis 
a. Axenfeld’s anomaly 
b. Rieger’s anomaly 
c. Peter’s anomaly 
d. Systemic hypoplastic mesodermal dysgenesis (Marfan’s syndrome) 
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e. Systemic hyperplastic mesodermal dysgenesis (Weill – 
Marchesani syndrome) 
2. Iridotrabeculodysgenesis (aniridia) 
B. Associated with phakomatoses and hamartomas 
1. Neurofibromatosis (Von Recklinghausen’s disease) 
2. Encephalotrigeminal angiomatosis (Sturge–Weber syndrome) 
3. Angiomatosis retinae (von Hippel-Lindau syndrome) 
4. Oculodermal melanocytosis (Nevus of Ota) 
C. Associated with metabolic disease 
1. Oculocerbrorenal syndrome (Lowe’s syndrome) 
2. Homocystinurea 
D. Associated with inflammatory disease 
1. Maternal rubella syndrome (congenital rubella) 
2. Herpes simplex iridocyclitis 
E. Associated with mitotic disease 
1. Juvenile xanthogranuloma (nevoxanthoendothelioma) 
2. Retinoblastoma 
F. Associated with other congenital disease 
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1. Trisomy 13-15 syndrome (Patau’s syndrome) 
2. Rubinstein–Taybi syndrome 
3. Persistent hyperplastic primary vitreous 
Hoskins–Shaffer–Hetherington (1984) clinical anatomic classification of the Developmental 
Glaucomas10.  
I. Isolated trabeculodysgenesis (malformation of trabecular meshwork in the absence of iris or 
corneal anomalies) 
A. Flat iris insertion 
1. Anterior insertion 
2. Posterior insertion 
3. Mixed insertion 
B. Concave (wrap-around) iris insertion 
C. Unclassified 
II. Iridotrabeculodysgenesis (trabeculodysgenesis with iris anomalies) 
A. Anterior stromal defects 
1. Hypoplasia 
2. Hyperplasia 
B. Anomalous iris vessels 
1. Persistence of tunica vasculosa lentis 
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2. Anomalous superficial vessels 
C. Structural anomalies 
1. Holes 
2. Colobomata 
3. Aniridia 
III. Corneoiridotrabeculodysgenesis (malformation of trabecular meshwork with iris and corneal 
anomalies) 
A. Peripheral 
B. Midperipheral 
C. Central 
D. Corneal size 
 Anomalies of the anterior segment may comprise the trabecular meshwork singly or it 
can be associated with defective development of the iris and cornea.  
Isolated trabeculodysgenesis is the only developmental ocular anomaly found in nearly 
half of infantile and juvenile Glaucoma. It is the characteristic defect in Primary Congenital 
Glaucoma. 
 
 
 
15 
EPIDEMIOLOGY OF PRIMARY CONGENITAL GLAUCOMA 
 Primary Congenital Glaucoma (PCG) is a rare disorder of the eye accounting for 0.01–
0.04% of total blindness. It generally manifests at birth or before the age of 3. The degree of 
occurrence differs with different populations. In developed western countries, the occurrence is 
reported to be about 1 out of 10,000 births11. The PCG is more prevalent in the presence of 
“founder effect” or a higher incidence of consanguinity in the community. The “founder effect” 
is described as a genetic mutation noticed prominently in a particular community due to the 
mutation seen in the gene of a single progeny or small group of progeny. 
The occurrence of PCG is reported to be 1 in 1250 among the Gypsies of the Slovakia12. 
While in the Middle Eastern countries, the incidence was found to be 1 in 2500 13.  In a 
retrospective study conducted at the Glaucoma unit at King Abdulaziz University Hospital 
(KAUH, Riyadh, Saudi Arabia) covering the period from 2006 to 2010, where approximately 
600 new Glaucoma patients are seen annually, Pediatric Glaucoma accounts for about 3% of 
which 2.7% are PCG14. In Andhra Pradesh, India, the incidence of PCG is 1 in 3300, accounting 
for 4.2% of all childhood blindness15. About 60% of the patients manifested the disease in the 
first 6 months of life while 80% were recognized to have the disease by first year of life. Males 
account for about 65%8. 
 Inheritance of PCG is usually sporadic in nature. In familial cases of Primary Congenital 
Glaucoma autosomal recessive pattern prevails, the penetrance of which can be incomplete or 
variable. The inheritance can also be multifactorial. Few cases of autosomal dominant and 
occasionally pseudo-dominant pattern of inheritance has also been identified. 10–40% of cases 
reported with the disease is familial with variable penetrance (40–100%) 11. 
16 
GENETICS 
 GLC3 has been designated by HUGO as the label for the gene(s) causing PCG. The 
chromosomal loci linked to PCG are GLC3A (2p21), GLC3B (1p36), GLC3C (14q24.3). 
GLC3A loci which harbors the human cytochrome P450 gene CYP1B1 (OMIM 601771), 
has been characterized16. More than 40 different mutations have been identified in CYP1B1 to be 
causative of PCG in various ethnic backgrounds thus highlighting the allelic heterogeneity of the 
condition.  
 The autosomal recessive inheritance pattern of PCG is well documented showing more 
prevalence in boys than in girls. Cases of incomplete penetrance have also been reported. 
Sarfarazi and associates 1995 mapped the locus GLC3A (MIM 231300) for PCG to the short arm 
of chromosome 2p22 to 21. However, some other PCG families in the same study failed to show 
linkage to the 2p22 to 21 region, implying locus heterogeneity for this condition. An additional 
PCG locus, GLC3B17, has been localized to chromosome 1p36.2-p36.1 in some families not 
showing linkage to the chromosome 2 markers. Confirmation of linkage between CYP1B1 and 
PCG in different populations have verified the GLC3A locus (CYP1B1) as a major cause of PCG 
accounting for 85%–90% of all familial cases and 27% of sporadic cases18. 
 Cytochrome p450 1B1 (CYP1B1) 
The Cytochrome p450 1B1 (CYP1B1) gene is located on chromosome 2 at position 2p21-22. 
It contains two introns and three exons and the open reading frame starts with exon II and ends 
within exon III. The protein product of this gene metabolizes a variety of xenobiotics and 
endogenous intermediary substrates. It is expressed in the ciliary body, nonpigmented ciliary 
epithelium, iris and TM. CYP1B1 is also involved in signaling pathways thereby regulating 
expression of many genes involved in growth, development and differentiation of various ocular 
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structures particularly those of the anterior chamber. Pathogenic mutations in CYP1B1 occur in 
PCG in varying frequencies; some are highly prevalent and others appear with different 
frequencies across population, mutations in CYP1B1 gene are the most common cause of PCG.  
 
(Fig. 1) Schematic representation of CYP 1B1 gene 
 
 
 
 
 
 
 
 
 MYOCILIN 
MYOC (chromosome 1 at 1q25) codes for myocilin/TIGR (trabecular meshwork-induced 
glucocorticoid response) protein. MYOC gene consists of two introns and three exons. Most 
tissues of the eye (trabecular meshwork, sclera, ciliary bodies, retina, etc.) express this protein. 
MYOC has been located in extracellular matrix of normal as well as glaucomatous trabecular 
meshwork. It codes for a sticky stress protein, which covers TM. Mutations in MYOC gene 
occur in a many types of eye disorders accounting for 2 to 5% cases of POAG and 5.5% of PCG 
cases. 
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FOXC1 
Another gene that is thought to play a role in the pathogenesis of PCG is Forkhead- 
related transcription factor C1 (FOXC1 or FKHL7). It is located on p-arm of chromosome 6 
(6p25).  
 LTBP2 
Recently linkage analysis of PCG in consanguineous Pakistani PCG families was 
reported with involvement of a new chromosomal locus adjacent to GLC3C on 14q24.2-24.3. 
The candidate gene identified was latent transforming growth factor-b-binding protein 2 
(LTBP2). Truncating mutation were identified in this gene in PCG patients. The expression 
pattern of LTBP2 in the trabecular meshwork, ciliary body and ciliary process has increased the 
complexity of the pathophysiological mechanism involved in PCG. 
 
(Fig 2) Schematic diagram of the LTBP2 gene 
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ANATOMY OF NORMAL ANGLE 
NORMAL ANGLE CONFIGURATION AT BIRTH 
 Gonioscopy done in a neonate’s eye shows the iris to be inserted into the angle wall 
behind the scleral spur with the visualization of the ciliary body band in front of the insertion of 
iris. Flat insertion of iris can be noted as the angle recess has not deepened. 
In the first 6 to 12 months of life, posterior sliding of the uveal tissue takes place as a 
continuous process, and can be seen as formation of angle recess gonioscopically8. 
Hence, adult angle configuration where the iris turns slightly posteriorly before inserting 
into the ciliary body is not usually found at the time of birth, and is reported to develop only in 
the first year of life. 
  Deep angle recess with visualization of the ciliary body band is a striking feature of the 
noenates eye which is not a feature of eyes with trabeculodysgenesis. 
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EMBRYOGENESIS 
The mesenchymal cells of neural crest cell origin gives rise to structures in the angle of 
the anterior chamber that are related to the aqueous drainage. The anterior chamber angle is 
occupied by loosely arranged mesenchymal cells and is undifferentiated until 8th month of intra 
uterine life, and the anterior chamber appears to be a slit-like opening. 
            Some hypotheses proposed to explain the formation of anterior chamber angle are: 
1. Atrophy or progressive resorption of a part of fetal tissue 
2. Cleavage or separation of two pre-existing layers of tissue due to differential growth rate, and 
3. Rarefaction: mechanical distention resulting from the growth of anterior ocular segment.  
According to the various studies that have been conducted to analyse the development of 
the angle structures, none of the above concepts are completely correct. 
 Anderson did extensive light and electron microscopic studies of 40 normal fetal and 
infant eyes and found that the anterior surface of the iris inserts at the edge of the corneal 
endothelium at 5 months of intra uterine life, covering the cells that eventually become the 
trabecular meshwork19. 
           Worst coined the term “fetal pectinate ligament” which delineates the corneoscleral 
meshwork primordium from the anterior chamber angle20. Just cleavage or atrophy does not 
include the developmental process. If so, the uveal tract would just split away from the 
corneoscleral shell and trabecular tissue. 
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 Trabecular meshwork gains exposure to the anterior chamber with the deepening and 
posterior movement of the angle recess. In progressively older tissue specimens, Anderson found 
a posterior repositioning of the anterior uveal structures which might be because of the 
differential growth rate. Hansson and Jerndal21 used scanning electron microscopy to study 
human fetal eyes and reported that at the beginning of the 5th fetal month, a single layer of 
endothelium, continuous with that of the cornea forms, extending over the angle of primitive 
anterior chamber and iridopupillary structures, forming a closed cavity. They also noted that, by 
the 7th fetal month, the endothelial layer of the anterior chamber angle begins to flatten, with 
indistinct margins. The endothelial layer becomes fenestrated and these cells start migrating into 
the underlying uveal meshwork by the final weeks of gestation and in the initial few weeks after 
birth. 
Shields’ theory of development of Anterior Chamber Angle: Shields observed the anterior 
chamber angle development and found that during gestation, at 5 months, a continuous layer of 
endothelium creates a closed cavity, and the anterior surface of the iris inserts in front of the 
primordial trabecular meshwork22. The endothelial membrane disappears from the pupillary 
membrane, iris, and anterior chamber angle progressively, possibly incorporated into the 
trabecular meshwork, during the third trimester. The peripheral uveal tissue begins to slide 
posteriorly in relation to the anterior chamber angle structures. The trabecular meshwork 
development begins in the inner, posterior aspect of the primordial tissue, progressing toward 
Schlemm’s canal and Schwalbe’s line. The normal anterior chamber angle becomes fully 
developed at the age of 1. 
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(Fig 3) Developmental mechanics of chamber angle 
 
Development of the normal angle structures comprises of bi directional growth.  Scleral 
spur shows an inward growth represented by the horizontal arrow accompanied by receding 
uveal meshwork represented by the vertical arrow. As the growth progresses there is obliteration 
of the fetal uveal meshwork leaving behind a few fine residual iris processes. When this normal 
developmental process comes to a halt, it results in persistence of the uveal meshwork leading to 
Congenital Glaucoma. 
 
23 
THEORIES OF ABNORMAL DEVELOPMENT IN PCG 
 Elevation of intraocular pressure in Primary Congenital Glaucoma is considered to be due 
to abnormal development of the angle structures causing reduced facility of aqueous outflow. 
Several major theories have been put forward. 
Mann’s Theory: 
       Mann in 1928, proposed that the arrest of the process of formation of the anterior chamber 
angle by atrophy of mesenchyme results in retention of abnormal tissue blocking aqueous 
outflow in PCG23.  
Incomplete Cleavage Theory: 
           Allen, Burian, and Braley (1955) noted that incomplete cleavage of mesoderm causes 
absence of angle recess in PCG, though cleavage theory for normal development is not proved24. 
 Barkan’s theory: 
                 Barkan in 1955 suggested that incomplete resorption of the mesodermal cells led to 
membrane formation across anterior chamber angle25. According to Barkan and Worst, a thin 
membrane, later termed as the Barkan’s membrane, is said to be covering the trabecular 
meshwork surface. Anderson and Maumenee were unable to prove the presence of this 
membrane despite extensive histologic studies with light and electron microscopy. Anderson 
suggests that thickened, compact trabecular beams in the meshwork area close to the anterior 
chamber resembles a membrane when visualized under the operating microscope. 
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Maumenee‘s theory: 
               In Infantile Glaucoma eyes, Maumenee (1958) noted an abnormal insertion of the 
ciliary muscle anteriorly over the scleral spur26. The ciliary muscle’s longitudinal and circular 
fibers inserts at the level of the trabecular meshwork instead of the scleral spur. He postulated 
that the scleral spur might be compressed forward and externally by these changes, thus 
narrowing the Schlemm’s canal. The absence of Schlemm’s canal in some histopathologic 
specimens was noted by Maumenee (1963), who suggested that this might be the cause of 
aqueous outflow being obstructed in Congenital Glaucoma. 
Worst theory:  
               Worst in 1966 proposed some of the atrophy and resorption concepts, rejecting the 
cleavage theory, and suggested that a high insertion of ciliary muscle’s longitudinal portion on 
the trabeculum is caused by an incomplete scleral spur development. 
 He also felt that during gestation, the anterior chamber angle is covered by a single layer 
of endothelial cells, and that ‘Barkan’s Membrane’ is constituted by its abnormal retention in 
PCG. Worst still believed this theory despite the lack of evidence to it. 
Smelser and Ozanics’ theory of failure of rearrangement:  
            Smelser and Ozanics (1971) explained that the anterior chamber angle mesoderm’s 
failure to become properly rearranged into the normal trabecular meshwork in PCG, a theory 
favored by light and electron microscopic studies.  
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Kupfer’s theory: 
           Kupfer and associates (1978) suggested that migration of abnormal neural crest cell and a 
defect of terminal induction by embryonic inducers causes several forms of congenital glaucoma. 
Anderson’s theory: 
Anderson in 1981, histopathologically proposed the high insertion of the anterior uvea 
into the trabecular meshwork, due to a developmental arrest in the uvea’s normal migration 
across the meshwork in the third trimester of gestation. He stated that, in PCG eyes the iris and 
ciliary body have failed to recede posteriorly, and hence the posterior portion of the trabecular 
meshwork is overlapped by the insertion of the iris and anterior band of ciliary body. He also 
believed that the normal posterior migrations of ciliary body and iris root is prevented by 
thickened trabecular beams in infantile glaucoma. 
Beauchamp’s theory: 
             Beauchamp and co-workers (1985) have postulated that abnormal extracellular matrix 
and glycoproteins interferes with adductors, inductors, receptors and specific time sequencing 
which leads to abnormal anterior segment development. According to them, the defects in 
morphogenesis and differentiation (capacitation) in Primary Congenital Glaucoma requires a 
minor ‘remodeling’ to become functional such as goniotomy. McMenamin (1991) noticed a 
marked increase in the extracellular matrix volume during development. Tawara and Inomata in 
1994 found extensive accumulations of basal lamina-like material containing heparan sulfate-
type proteoglycans in the thick subcanalicular tissue in trabeculectomy specimens from patients 
with Developmental Glaucoma.  
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 In summary, primary congenital glaucoma appears to be a result of anterior chamber 
angle tissue’s a developmental abnormality derived from neural crest cells, one or more of 
various mechanisms causing aqueous outflow obstruction. 
 The arrest of development may cause an anterior insertion of iris and the ciliary muscle 
directly into trabecular meshwork, and only a rudimentary scleral spur may be seen. The 
trabecular beams may be compressed due to the high insertion of the ciliary body and iris into 
the posterior portion of the trabecular meshwork and the extracellular matrix could be abnormal. 
There may also be primary developmental defects at various levels of the meshwork and in 
Schlemm’s canal in certain cases, although, a true membrane over the meshwork does not appear 
to be a feature of this disorder. 
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EVALUATION OF PCG 
  PCG is a characteristic type of Developmental Glaucoma caused by an isolated 
anomalous development of the trabecular meshwork, not involving other ocular maldevelopment 
or pathology that can elevate the intao ocular pressure.  
Symptoms:   The ‘classic triad’ of symptoms27 in Congenital Glaucoma includes 
1. Epiphora 
2. Photophobia  
3. Blepharospasm (attributed to IOP-induced corneal epithelial edema). 
4. Ocular enlargement occurs because the neonatal globe is still distensible. The corneal and 
scleral collagen have not hardened sufficiently to prevent their expansion with increased 
intraocular pressure. This change includes stretching in all parts of the infant eye, 
including the cornea, the anterior chamber angle, the sclera, the optic nerve, the scleral 
canal, and the lamina cribrosa28. However, presence of prominent eyeball and cloudy 
cornea which is the result of corneal edema are the common presentations of the 
condition in the Indian population. 
 A mandatory thorough clinical evaluation is required. Child’s response to light can be 
checked by using a dim light source. Vision should be assessed by age-appropriate methods.  
Posterior segment pathology should be looked for, using ultrasonography when fundus cannot be 
visualized. 
 The primary method of evaluation involves an examination under anesthesia (EUA), 
preferably under the operating microscope. Examination under sedation is often adequate for 
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brief examinations, and general anaesthesia may be needed when a prolonged examination and 
surgery are required. The following are to be documented during EUA: 
1. Corneal findings: to measure corneal diameter to look for corneal clarity, Haab’s striae 
a. A corneal diameter more than 12 mm before the age of 1is indicative of PCG. 
Enlargement of the cornea in PCG basically occurs until the age of 3, but the 
sclera can undergo stretching upto the age of 10. Separate measurements of the 
corneal diameters are to be taken in both the horizontal and vertical meridians. 
Calipers should be used for the measurement. 
b. Edema of the cornea in PCG starts at the epithelial level due to raised IOP which 
eventually results in permanent stromal edema. If not treated promptly, the edema 
worsens leading to permanent scarring of the stroma and thus increases the 
astigmatic index. 
c. The acute elevation of IOP results in damage to the corneal endothelium and 
stretching of the Descemet’s membrane leading to breaks in these layers30. Since 
this was first described by Haab, these striae are named after him. These striae are 
typically horizontal and linear when they occur centrally in the cornea, but 
parallel or curvilinear to the limbus when they occur peripherally. 
 
Age Corneal diameters (mm) 
Normal Possible Glaucoma 
Newborns 9.5–10.5 11.5–12.0 
1 year 10–11.5 12.0–12.5 
2 years 11.5–12 12.5–13.0 
3 years 12 13.0–14.0 
**Data obtained from Morin et al 
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(Fig 4) Corneal edema in a case of congenital glaucoma 
 
(Fig 5) Measurement of corneal diameter using calipers 
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(Fig 6) Haab’s Striae 
 
Direct Gonioscopic lenses used in infants: 
Fig 7) Richardson-Shaffer lens (L) is a miniature of Koeppe lens (R)  
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2. IOP: The mode of anesthesia and the method of tonometry are of utmost value. Almost 
every anesthetic agents varies the IOP, seemingly in relation to the level of anesthesia 
and as a direct function of their effect on cardiovascular tone. A rapid lowering of IOP 
occurs particularly with halothane, while transient elevation can occur with cyclopropane 
or succinylcholine. In recent years, halothane has been largely replaced by sevoflurane 
because of its rapid onset of action, faster recovery time and lower incidence of reported 
side effects. However, sevoflurane shares the IOP-lowering effect of halothane and it has 
been suggested that IOP should be checked immediately after intubation to avoid falsely 
low recordings. Anesthetic drugs that achieve only light anesthesia and those that induce 
deeper anesthesia only slowly, such as diethyl ether, cyclopropane or ketamine31, allow 
the IOP to be measured somewhere between the artificially elevated IOP of “excitement” 
stage of anesthesia and the artificially lowered pressure of deep anesthesia observed with 
halothane. The possible effect of ketamine on IOP has been controversial. Some studies 
report that ketamine elevates IOP, whereas others suggest that the impact on IOP is 
comparatively modest. Regarding the type of tonometer, Perkins hand-held applanation 
tonometer or electronic (Tonopen) tonometer is commonly employed. Our preference is 
the Perkins tonometer. The normal IOP in an infant is slightly lower than in an adult, but 
21 mm Hg remains a useful upper limit. 
3. Gonioscopy: Direct gonioscopic lens with a hand-held illuminating source and binocular 
microscope provides a good view of the angle. In the normal newborn eye, the iris 
usually inserts posterior to the scleral spur. In PCG, the iris commonly inserts anteriorly 
directly into the trabecular meshwork. This iris insertion is most commonly flat, although 
a concave insertion may be rarely seen.  
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Loch Ness Monster phenomenon32: Although the angle is usually avascular, loops of 
vessels from the major arterial circle may be seen above the iris producing a “sea serpent 
appearance”. Sometimes, the peripheral iris may be covered by a fine, fluffy tissue 
which is termed “Lister’s morning mist” sign. 
4. Ophthalmoscopy:  The Infant Glaucomatous Cup usually has a configuration different 
from Adult Glaucomas. Although it can be oval, it is more commonly round, steep-
walled and central, surrounded by a uniform pink rim. The cup tends to enlarge 
circumferentially with glaucomatous progression, which probably results from stretching 
of the scleral canal. Although this pattern of cupping can develop early and rapidly in 
infants with Glaucoma, striking reversal of cupping may result with IOP reduction after 
successful surgery33. But this reversal of cupping is not evident in adults and children 
(especially older ones) with advanced glaucoma suffer irreversible thinning/notching of 
neuro-retinal rims. 
5. Refraction, using streak retinoscope 
Interpretation of examination findings: 
 After EUA, increased corneal diameter, increased cup disc ratio and prominent eye balls 
proves the presence of PCG indicating the need for surgery. The effect of various anesthetic 
agents on the IOPshould be kept in mind while interpreting the result. In the absence of 
characteristic features of PCG, diagnosis and treatment may be postponed, and after 3–4 weeks, 
a repeat EUA may be done to confirm progression, if any. 
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DIFFERENTIAL DIAGNOSIS OF PCG 
I.  Other causes of Glaucomas 
A. Glaucoma associated with any congenital anomaly 
B. Secondary Glaucoma 
II. Other causes of prominent/ hazy cornea 
A. Megalocornea 
B. Sclerocornea 
C. High myopia 
D. Metabolic diseases 
1.  Cystinosis 
2. Mucopolysaccharidoses 
3. Hand-Schüller-Christian disease (histiocytosis) 
4. Acrodermatitis enteropathica 
5. Peroxismal disorders 
6. Zellweger syndrome 
E. Posterior polymorphous dystrophy 
F. Congenital hereditary endothelial dystrophy 
G. Birth trauma 
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H. Inflammatory conditions of the eye 
III. Other causes of watering of eyes or photophobia 
A. Congenital Nasolacrimal duct obstruction 
B. Conjunctivitis 
C. Corneal abrasion 
D. Meesman’s corneal dystrophy 
E. Reis-Buckler’s dystrophy 
IV. Other causes of optic nerve head changes 
A. Pit 
B. Coloboma 
C. Hypoplasia 
D. Tilted disc 
E. Large physiologic cup 
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MANAGEMENT 
Overview of management 
 Primary goals in the management of Congenital Glaucoma includes the following. 
1. To control the intraocular pressure in order to prevent loss of visual acuity 
2. To preserve visual field  
3. To maintain the ocular integrity 
4.  To stimulate the development of binocular stereoscopic vision in the affected child. 
 
Anxiety of the parents should be addressed first. Proper sensitization regarding the nature of 
the disease and the progression should be given to the parents. Emphasis on regular follow up 
examinations, drug compliance and possibilities of re-surgeries. The physician should never 
forget the importance of amblyopia management in recalcitrant cases.  
 
Medical therapy is usually a supportive management. Laser therapy is not of much benefit in 
these cases. Surgical treatment is the ideal treatment of choice in most of the developmental 
Glaucomas. Goniotomy or trabeculotomy are the initial lines of management.  In India, hazy 
cornea precludes goniotomy in most of the cases. In case of failure of prior procedures combined 
trabeculotomy with trabeculectomy has proved to be helpful. In refractory cases 
pharmacologically modified trabeculectomy or glaucoma drainage implants may be needed. 
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Medical therapy 
Medical therapy is a temporary management. Topical drugs help in alleviating the IOP, to 
reduce the corneal edema so that surgical intervention can be carried out. 
1. Beta-blockers: Beta-blockers reduces IOP by decreasing aqueous formation with little or 
no effect on the outflow facility. Beta-blockers used in congenital glaucoma include 
Betaxolol 0.25%, Levobunolol 0.25%, Timolol solution 0.25%, and Timolol gel-forming 
solution 0.25%. Plasma timolol levels in children after treatment with 0.25% timolol 
greatly exceed those in adults after instillation of 0.5% timolol, especially in infants. 
Increased plasma timolol levels in children are explained by the volume of distribution of 
the drug, which is much smaller in children compared with adults. Higher plasma levels 
of drug would be expected to be associated with an increased risk of systemic side effects 
in children, especially young children, compared with adults. 
The drug should be used with extreme caution in neonates due to the possibility of 
apnea and other systemic side effects35. Exacerbation of bronchial asthma can occur in 
children. Hence it is not recommended in pediatric age group. Betaxalol which is a 
selective β1 antagonist is preferred. 
2. Carbonic anhydrase inhibitors (CAIs): this can be used both systemically and topically in 
the management of Glaucoma. It acts by reducing the aqueous humour formation by 
reversible non-competitive binding with the enzyme type2 C-type carbonic anhydrase 
which is the predominant enzyme in ciliary process. Growth suppression in children has 
been associated with oral acetazolamide therapy, and infants may experience a severe 
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metabolic acidosis. Oral administration of acetazolamide suspension at a dosage of 10 
(range 5–15) mg/kg/day given in divided doses (three times daily) is safe and well 
tolerated by children, lowers IOP and may reduce corneal edema prior to surgery. Topical 
versus oral CAI therapy has been evaluated for Pediatric Glaucoma in a crossover design 
study. The mean IOP was reduced by 36 and 27% compared with baseline, after 
treatment with oral acetazolamide and topical dorzolamide, respectively. All eyes showed 
an increase in IOP when switched from acetazolamide to dorzolamide, with a mean 
increase of 3.7 mm Hg. Although not as effective as acetazolamide in this group of 
patients, topical dorzolamide caused a significant reduction of IOP and was well 
tolerated. 
3. Prostaglandin analogues: Latanoprost (0.005%) and travoprost (0.004%) act on the FP 
receptors and produce a decrease in IOP by increasing the uveoscleral outflow without 
any effect on aqueous production, trabecular outflow and episcleral venous pressure. 
Several studies also indicate that they also produce a change in the structure of the 
uveoscleral meshwork - ECM remodelling, widening of intermuscular spaces in the 
longitudinal ciliary muscle and dissolution of type 1 & 3 collagen. Bimatoprost (0.03%) 
is a prostamides, which donot act through PG receptors. It acts by inhibiting the enzymes 
metabolising PGs which increases both uveoscleral and trabecular outflows. According to 
various studies latanoprost proved to cause sufficient reduction in IOP in children. 
Parents should be educated about the probable side effects of the drug. 
4. Alpha-2 agonists: Brimonidine should be avoided in pediatric patients under the age of 5. 
5. Other drugs: IOP may be reduced temporarily before surgery in patients with 
developmental glaucomas by administering osmotic drugs such as mannitol. 
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Surgical Management 
Introduction 
 Prompt surgical intervention is the definitive treatment of congenital glaucoma. 
Goniotomy may be performed if cornea is relatively clear to permit view of the angle structures 
at the time of referral for treatment. Goniotomy cannot be done if patients present with corneal 
clouding. In such cases, the procedure of choice is initial external trabeculotomy. If initial 
trabeculotomy is not successful, trabeculotomy combined with trabeculectomy may be 
performed. 
Most patients present with characteristic features of congenital glaucoma soon after birth 
or within 6 months of birth. But some cases can present late in the first year. In advanced cases, 
combined procedures proved to be beneficial. 
Goniotomy  
 The goal of Goniotomy is to to eliminate the hindering element that causes impedence to 
aqueous outflow, hence it restores the conventional outflow of aqueous through the trabecular 
meshwork in to the Schlemm’s canal. 
Various surgical gonioscopic lenses are available. Swan-Jacob lens is very convenient to 
use.  Barraquer knife, Worst knife, Swan blade can be used to perform goniotomy. Under general 
anesthesia (GA), under the operating microscope, goniotomy is to be done after fixing the globe 
with bridle suture. 
The surgeon should sit opposite to the angle that is to be incised. The goniotomy knife is 
used to do the paracentesis, through clear peripheral part of the cornea, about 1 mm inside the 
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limbus. Once the anterior chamber is entered, the blade must be clearly seen throughout the 
procedure. The goniotomy knife must be advanced above and parallel to the surface of the iris, 
across the pupil toward the trabecular meshwork near the opposite limbus. 
The knife tip must be directed slightly ahead of the middle portion of the trabecular 
meshwork. It should be made to depress the trabecular meshwork and then circumferential 
sweeping movement should be done with the knife as it cuts the trabecular tissue over 90 to 120o. 
Cut of uniform depth throughout the incision. 
Following the incision, a white line is visible posterior to the blade, which is 
accompanied by posterior movement of the iris as the angle deepens. Mild hyphema usually 
occurs on withdrawing the blade. Goniotomy surgery is reported to have a success rate of 80% in 
congenital glaucoma37. 
Even though goniotomy is more successful when glaucoma is recognized early and 
treated promptly before one year of age, successful control is achieved in patients up to 2 years 
of age. Endoscope assisted goniotomy is tried to improve the results. 
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(Fig 7) Goniotomy: The illustrated gonioscopic cross-section shows exact location of 
incision in abnormal trabecular meshwork. 
 
 
 
(Fig 8) Swan Jacob Goniolens 
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Advantages of Goniotomy: 
1. Conjunctiva is preserved, hence this procedure doesn’t interfere with the success of 
future filtering surgery, if needed. 
2. Precise location of the incision is aided by direct visualization of the angle 
3. It is a safe procedure as its less traumatic 
4. Duration of the surgery is less 
5. Procedure can be repeated 
6. Incidence of significant hypotony is low 
7. Bleb related complications are avoided 
Disadvantages of Goniotomy: 
1. Technically difficult 
2. Need for special instrumentation 
3. Procedure cannot be done if the details of the angle structures are not clearly seen. 
Trabeculotomy ab externo 
  A fornix-based or limbus-based conjunctival flap is made, followed by a partial 
thickness scleral flap as it is done in trabeculectomy, and Schlemm’s canal is then deroofed by 
incising midway between the anterior bluish-gray area and the posterior white scleral area. 
The lower arm of the Harms’ trabeculotome is introduced into the canal using the upper 
parallel arm as a guide. Once 90% of the trabeculotome is within the canal, it is rotated into the 
anterior chamber. Rotation of the trabeculotome is continued until 75% of the probe arm length 
has entered the chamber, then the rotation is reversed and the instrument is withdrawn. About 2 
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to 2 1 / 2 clock hours of the internal wall of Schlemm’s canal and trabecular meshwork are 
disrupted by the rotation of the trabeculotome into the anterior chamber. The trabeculotomemis 
then passed into the Schlemm’s canal on the other side of the radial incision and rotated into the 
anterior chamber. 
In total, about 100 to 120 degrees of trabecular meshwork is ruptured by this technique. 
This establishes direct contact between the anterior chamber and schlemm’s canal. Scleral flap 
must be sutured tightly with 10-0 nylon and the conjunctival flap with 8-0 vicryl. Various studies 
have proved that trabeculotomy outstands goniotomy, as the initial procedure however in few 
studies both the procedures faired equally well 
Trabeculotomy ab externo has a lot of advantages over Goniotomy38.  
1. It can even be done in edematous or scarred cornea. 
2. Breakthrough of the inner wall of the Schlemm’s canal and trabecular 
meshwork can be more accurately.  
3. Sharp instruments need not be introduced into the AC.  
4.  Can be performed under operating microscope thus it precludes the need for 
special gonioscopic lens.  
5. Can be repeated 
6. Can be converted to trabeculectomy if needed 
7. Can be combined with trabeculectomy to achieve better results 
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Disadvantages of Trabeculotomy includes  
1. Damage to the conjunctiva can interfere with the outcome of future filtering surgery 
2. Special trabeculotomy probes are needed 
3. Altered limbal anatomy especially in severe cases of buphthalmos makes the 
identification of sclemm’s canal difficult 
4. Schlemm’s canal is not found in 4 to 20 % of the cases 
5. Conversion of trabeculotomy entry site to trabeculectomy makes the sclerostomy site 
very close to the root of iris which predisposes to iris tissue incarceration 
6. Undesirable external filtration can occur 
Anomalous angle type is found to be the only factor influencing the success of 
trabeculotomy ab externo. However, the success of Goniotomy relies upon the stage of 
glaucoma, corneal diameter or the presence or absence of hazy cornea. Studies have proved that 
goniotomy is successful in about 64–77% of eyes, while trabeculotomy controls IOP in over 
90% of eyes. However, no prospective, controlled trials are available to compare the success rate 
of both the procedures in the same study. 
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(Fig 9) The Harms’ trabeculotomes 
 
(Fig 10) The trabeculotome is passed into Schlemm’s canal 
 
(Fig 11) The trabeculotome is rotated into the anterior chamber 
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Modifications of Trabeculotomy: 
Beck and Lynch introduced a modification in trabeculotomy using prolene suture. 360 
degree trabeculotomy can be done in a single procedure by threading a 6–0 polypropylene suture 
through the schlemm’s canal in patients with Primary Congenital Glaucoma. The refined 
technique can be performed via a single nasal surgical site. Advantages of this technique are this 
avoids many of the difficulties encountered with metal trabeculotomes and preserves conjunctiva 
for future filtering Glaucoma surgery. Diadvantages includes difficulting in threading the suture 
throughout the canal length, hypotony and misdirected sutures. 
Gonioscopy-assisted transluminal trabeculotomy (GATT) 
      This is a new, minimally invasive, ab interno procedure using a fiberoptic catheter with 
illuminated tip which allows visualization of the tip of the catheter as it is threaded through the 
canal of Schlemm39. It is demonstrated to be safer than suture trabeculotomy. Most common 
complication was transient hyphema. 
Primary Trabeculectomy 
Though it is technically easier than goniotomy or trabeculotomy it is not a first-line 
procedure in congenital glaucoma, due to higher incidence of bleb related complications and 
lower rates of success.  
Trabeculectomy with mitomycin-C 
 Filtering surgery is indicated when one or more angle surgeries failed tocontrol the 
disease progression. Fornix-based flaps are preferred in both infants and children. Intraoperative 
use of mitomycin-C improves the outcome of this procedure to some extent, however with side 
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effects of its own. IOP control was achieved in 66% at 30 months in a series of 38 eyes, which 
mostly had uncontrolled PCG was reported by Mandal and associates40. Varied outcomes were 
reported in multiple studies using mitomycin-C doses ranging from 0.2 to 0.5 mg/ml applied for 
about 2 to 5 minutes has been reported by other authors; in most of these series, bleb-related 
infections have been reported. 
Combined Trabeculotomy with Trabeculectomy 
 As in a routine trabeculectomy, Kelly’s descemet’s punch can be used in removing a 
small rectangular strip of sclera from the deep scleral flap by after performing a trabeculotomy  
 Drainage Devices: 
         These devices may be inserted under the conjunctiva to make a communication between 
the anterior chamber and the subconjunctival space in recalcitrant cases. Glaucoma drainage 
implants are useful when other surgical treatments have a poor prognosis for success, prior 
conventional surgery fails, or when significant conjunctival scarring precludes filtration surgery 
Available types of drainage implants may be characterized as open tube (non-restrictive) devices 
or valved (flow-restrictive) devices. Open tube implants include the Molteno and Baerveldt 
implants, whereas the Krupin implant and the Ahmed Glaucoma Valve are flow-restrictive 
devices. Reported complications include hypotony with shallow anterior chamber and choroidal 
detachments, tube–cornea touch and corneal edema, obstructed tube, exposed tube or plate, 
endophthalmitis, and retinal detachment. 
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Follow-up:  
Emphasis should be laid on amblyopia treatment resulting from scars in the visual axis 
and anisometropia. Although stretching of the globe is compensated by the flattening of the 
cornea, there is still some amount of residual myopia which must be corrected. Many cases land 
up with irregular astigmatism. As the anisometropia is varies with time repeated cycloplegic 
refraction should be done. Need for frequent change of spectacles must be instructed. 
 Recognition of amblyopia warrants occlusion therapy. Hence a collaborative approach 
including ophthalmologist and pediatrician maximizes the child’s visual rehabilitation. 
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1. Molecular and Clinical Evaluation of Primary Congenital Glaucoma in Kuwait; Suad 
Alfadhli; Am J Ophthalmol 2006; 141:512–516 
Mutations in CYP1B1 gene were identified in more than 85% of PCG-affected families 
in Saudi Arabia. Mutation in this gene was also found to be common in Turkey and Slovakia. 
Only 48% of patients with PCG in France had the CYP1B1 gene mutations, whereas Curry and 
associates in 2004 concluded that mutations of CYP1B1 are not a major cause of PCG in 
Ecuador. A cohort of 17 PCG patients was screened for the presence of mutations in the coding 
part of this gene in Kuwait. The overall mutation rate of the CYP1B1 gene in Kuwaiti PCG 
patients was 22 out of 34 studied chromosomes (64.7%). 
2. Molecular genetics of primary congenital glaucoma; Mansoor Sarfarazi, Ivaylo Stoilov; 
Eye (2000) 14, 422-428 
The primary molecular defect underlying the majority of PCG cases has been determined as 
mutations in the enzyme cytochrome P450lBl. The CYPIBI gene has been found and reported to 
be expressed in the tissues of the anterior chamber angle of the eye. Molecular modelling 
experiments have suggested that the mutations observed in PCG patients interfere with the 
integrity of the CYPIBI molecule as well as its ability to adopt normal conformation. Based on 
these observations, we hypothesise that CYPIBI participates in the normal development and 
function of the eye by metabolising essential molecules that are probably used in a signalling 
pathway. 
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3. Mutation spectrum of the CYP1B1 gene in Indian primary congenital glaucoma 
patients; Aramati Bindu Madhava Reddy, Kiranpreet Kaur, Anil Kumar Mandal; 
Molecular Vision 2004; 10:696-702 
Mutations in CYP1B1 have been associated with PCG with varying frequencies across 
different ethnic communities and geographical boundaries. Populations with higher rate of 
inbreeding and consanguinity exhibit a higher frequency of CYP1B1 mutations in PCG as 
opposed to ethnically diverse populations. Screening a cohort of 64 consecutive PCG cases from 
different geographical locales of India revealed 37.50% (24/64 cases) mutations in CYP1B1. Of 
these 24 cases, consanguinity was seen in 16 cases and 3 of them had a positive family history. 
The involvement of CYP1B1 in PCG was found to be lower (37.50%) in our population than 
those reported in Saudi Arabian (95.0%) and Slovakian Gypsy populations (100%). This could 
be due to a higher rate of inbreeding and allelic homogeneity in these populations.  
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AIM AND OBJECTIVES OF THE STUDY 
OBJECTIVES: 
• To do clinical evaluation of primary congenital glaucoma  
• Identification and analysis of polymorphism in CYP1B1 gene in patients diagnosed to 
have PCG. 
• Isolation of genomic DNA from clinical blood samples 
• Amplification of CYP1B1 gene exon from genomic DNA using Polymerase Chain 
Reaction 
• Sequencing of amplified product and analysis of polymorphic variations 
METHODOLOGY: 
Patients of age 0 to 10, diagnosed to have Buphthalmos and in whom secondary causes of 
glaucoma were ruled out are registered for this study. Detailed clinical evaluation was done 
including measurement of corneal diameters, measurement of intraocular pressure and fundus 
examination. Blood samples will be collected from patients and their relatives after informed 
consent. DNA isolated from these samples will be subjected to PCR for amplifying the coding 
exons of the CYP1B1 gene using gene-specific oligonucleotide primers. PCR products will be 
sequenced and analyzed to determine the prevalence of common mutations and establish a 
genetic basis in understanding the pathology of PCG. 
SAMPLE SIZE: 
20 cases of PCG 
STUDY CENTRE: 
Regional Institute of Ophthalmology and Government Ophthalmic Hospital, Chennai 
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Subject Selection: 
Inclusion Criteria: 
Pediatric patients with the following criteria will be included in the study 
1. Increased corneal diameter (>12.0 mm), 
2. Raised intraocular pressure (>21 mmHg) and/ or presence of Haab’s 
striae, 
3. Optic disc changes (where examination was possible). Symptoms of 
epiphora and photophobia were the additional inclusion factors. 
4. Age of onset- from birth to one year 
5. Patients previously diagnosed to have Primary Congenital Glaucoma and 
on treatment will be included. 
Exclusion Criteria: 
1. Patients with secondary causes of Glaucoma 
2. Age of onset after 1 year 
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MATERIALS AND METHODS OF GENETIC ANALYSIS 
Reagents and Chemicals: 
 Preparation of 10X TEBbuffer done using Tris – 10.8 g, Boric acid – 5.5g, EDTA – 
0.93 g and made up to 100ml using distilled water. 
 Reagents for Polymerase Chain Reaction: 
o 10 X Taq DNA buffer compositions -100 mM Tris-HCl (pH 8.3), 500 mM KCl 
and 15 mM MgCl2. dNTP’s  (dATP, dGTP,  dCTP, dTTP - 250 µM each) 
o Mutated Forward primer (FP) 5 pM/µl, Reverse primer (RP) 5 pM/µl 
o Taq DNA polymerase (0.6 U/µl),Template DNA (approx 50 – 100 ng) with 
Sterile distilled water 
Primer sequence: 
Forward primer sequence for CYP1B1 5’-TCTCCAGAGAGTCAGCTCCG-3’ 
Reverse primer sequence for CYP1B1 5’-GGGTCGTCGTGGCTGTAG-3’ 
 
DNA Isolation from Blood or Body Fluids (Spin Protocol): 
Genomic DNA was isolated using Qiagen DNA isolation kit. The manufacturer protocol 
was followed. 
Amplification OF CYP1B1 Gene Using PCR was done. 
PCR Reaction Condition: 
 Initial denaturation 95ºC – 10 mins, Denaturation 95 ºC – 1 min 
 Annealing 55 ºC – 1 min, Extension 72 ºC – 1 min  
 Final extension 72 ºC -10 mins, Final hold 4 ºC  
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Gradient PCR Reaction Condition: 
 Initial denaturation 95ºC – 10 mins, Denaturation 95 ºC – 1 min 
 Annealing 54 ºC to 62 ºC – 1 min, Extension 72 ºC – 1 min  
 Final extension 72 ºC -10 mins, Final hold 4 ºC  
 Agarose Gel Electrophoresis was done. Then the gel is taken when the loading dye 
reaches the end of the gel. Then the DNA bands are visualized using UV in gel doc.  
Large scale amplification PCR was carried out. 
Gel Elution of Amplified product: 
       Amplified gene products were gel purified and elute using Qiagen gel extraction kit as 
described below 
Protocol: 
 The DNA fragment from the agarose gel was sliced using clean and sharp scalpel. 
 The chopped gel was weighed in a microfuge tube, three volumes of buffer QG were 
added to one volume of gel (100 mg is approximately to be 100 µl). 
 Microfuge tube was kept in preheated dry bath for 10 mins (or until the gel gets 
completely dissolved). It was vortexed every 2-3 mins to dissolve the gel. 
 One volume of isopropanol to the one volume of gel was added to the sample and mix. 
 Qiagen column was placed in a provided 2 ml collection tube. 
 Transfer 700 µl of mixture into the column and then centrifuged for 2 min at 11,000 rpm. 
Flow through was discarded and the Qiagen column was placed back into the same tube. 
The DNA get binds to the column. 
 To wash, add 750 µl of PE buffer into the Qiagen column and centrifuged at 11,000 rpm 
for 1 min. Flow through was discarded and the Qiagen column was placed back into the 
same tube. 
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 The Qiagen column was centrifuged again as empty at 11,000 rpm for 2 mins to remove 
residual of wash buffer. 
 Then the column was placed into a clean 1.5 ml micro centrifuge tube. 
 The DNA was eluted by adding 50 µl of EB (elution buffer) and centrifugation of column 
at 11,000 rpm for 1min. 
 Then the purified DNA was analyzed on a 1% agarose gel electrophoresis.    
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RESULTS AND ANALYSIS OF CLINICAL EVALUATION 
 
 
TABLE 1:  AGE AT PRESENTATION 
 
 
 
 
 
CHART 1:   AGE AT PRESENTATION 
 
 
 
Out of the 20 children who were diagnosed to have Primary Congenital Glaucoma before 
the age of 1, 10 % of the children presented with symptoms of PCG within 1 month after birth, 
65 % of them presented within 1 to 6 months of age and 25 % of them presented after 6 months.  
 
                                     
AGE AT PRESENTATION n % 
<1M 2 10% 
1-6M 13 65% 
7-1Y 5 25% 
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TABLE 2: SEX DISTRIBUTION 
 
SEX DISTRIBUTION n % 
Male 10 50 
Female 10 50 
 
 
CHART 2: SEX DISTRIBUTION 
 
 
 
The sex distribution in the subjects enrolled in the study is shown in this chart. 50 % of 
the children included were males and 50 % of them were females. 
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TABLE 3: CLINICAL SYMPTOMS 
 
 
 
 
 
 
CHART 3: CLINICAL SYMPTOMS 
 
 
 
An analysis of the various symptoms with which patients present in congenital glaucoma 
was done. 40 % of the children were brought with complaints of Buphthalmos (B) which is 
marked enlargement of eyes, along with photophobia (P) and lacrimation (L). 35 % of the 
children presented with Buphthalmos only. 15 % of the children were brought with both 
Buphthalmos and photophobia. 10 % of the children were brought with photophobia and 
lacrimation, where marked enlargement of eyes was either absent or unnoticed by the parents. 
SYMPTOMS n % 
B 7 35 
B,P,L 8 40 
B,P 3 15 
P,L 2 10 
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TABLE 4: PROPORTION OF CHILDREN BORN OF CONSANGUINEOUS MARRIAGE 
 
 
 
 
 
 
 
CHART 4: PROPORTION OF CHILDREN BORN OF CONSANGUINEOUS MARRIAGE 
 
 
 
 
Out of the 20 children, 25 % of them were born of 2nd degree consanguineous marriage, 
10 % were born of 3rd degree consanguineous marriage. Remaining 65 % of them were born of 
non-consanguineous marriage.   
CONSANGUINITY n % 
2nd  degree 5 25 
3rd degree 2 10 
Non consanguineous marriage 13 65 
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TABLE 5: IOP IN MMHG 
 
IOP n % 
<20 2 5% 
21-30 16 40% 
31-40 16 40% 
41-50 6 15% 
 
 
 
CHART 5: IOP IN MMHG 
 
 
 
This chart depicts that 40 % of the children in the study group had IOP of 21 to 30 mmHg 
and 40 % had IOP of 31 to 40 mmHg. 15 % of them had IOP above 40 and 5 % had less than 
20mm Hg. 
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TABLE 6: MEASUREMENT OF CORNEAL DIAMETER 
CORNEAL 
DIAMETER(mm) HORIZONTAL VERTICAL 
10 TO 11 20% 22.5% 
12 TO 13 45% 55% 
14 TO 15 35% 22.50% 
 
 
CHART 6: MEASUREMENT OF CORNEAL DIAMETER 
 
 
 
 
Measurement of corneal diameter in the subjects showed that 55 % of the eyes had 
vertical diameter of 12 to 13mm, 22.5 % of the eyes had diameter of 14 to 15 mm and 22.5% had 
diameter of 10 to 11mm. Horizontal diameters were measured to be 10 to 11mm in 20 % 12 to 
13 mm in 45% and 14 to 15 mm in 35%. 
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TABLE 7: PROPORTION OF PATIENTS WITH CORNEAL CLOUDING 
 
 
 
 
 
Only 5 % of the eyes had clear cornea. 62.5 % of eyes had mild haze where fundus could 
still be visualized. 32.5% had severe haziness where it was not possible to visualize the fundus. 
 
CHART 7: PROPORTION OF PATIENTS WITH CORNEAL CLOUDING 
 
 
 
 
 
 
CORNEAL CLARITY n % 
CLEAR 2 5% 
MILD HAZE 25 62.5% 
SEVERE HAZE 13 32.5% 
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TABLE 8: LATERALITY OF PCG 
 
 
 
 
 
 
CHART 8: LATERALITY OF PCG 
 
 
 
90 % of the children in the study group had bilateral manifestations of PCG. 10 % had 
unilateral involvement. 
 
 
 
LATERALITY n % 
BILATERAL 18 90% 
UNILATERAL 2 10% 
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TABLE 9: CUP DISC RATIO 
 
 
 
 
 
 
 
CHART 9: CUP DISC RATIO 
 
 
 
 
Fundus view was not possible in 35 % of the eyes due to corneal clouding. 10% of the 
eyes had CD ratio of 0.3 to 0.4. 33% of the eyes had a CD ratio of 0.5 to 0.6. 13 % had CD ratio 
of 0.7 to 0.8. 10% of the eyes had 0.9 cupping. 
 
 
 
FUNDUS n % 
NO VIEW 14 35% 
0.3-0.4 4 10% 
0.5-0.6 13 33% 
0.7-0.8 5 13% 
0.9- 4 10% 
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RESULTS OF GENETIC ANALYSIS 
DNA was isolated from the patients included in the study by Qiagen DNA isolation kit. 
PCR amplification was done for the selected regions and the amplified product was found to 
have a molecular weight of 786 bp of exon 2.  
 
Agarose Gel for Checking the Presence of Genomic DNA from the Collected Samples:  
Blood samples were taken from affected patients and their relatives.  Genomic DNA was 
extracted from the collected sample. The presence of isolated genomic DNA was checked in 
agarose gel. The genomic DNA isolated from the samples were analysed for concentrations as a 
prerequisite for amplification. 
 
(Fig 12) Agarose Gel for Checking the Presence of Genomic DNA from the First Set of 
Collected Samples 
 
 
 
 
 
 
 
 
 
 
To confirm the presence and quality of genomic DNA, the isolated genomic DNA were 
subjected to PCR to amplify the housekeeping gene, GAPDH, using oligonucleotide primers. As 
expected, the PCR product showed an amplified band between 400 to 500 base pairs which 
confirmed that the isolated genomic DNA are of good quality and can be subjected to the PCR 
amplification of Congenital Glaucoma specific genes for polymorphic studies. 
 
LANE 1, 2 & 3 - sample 1  
LANE 4, 5 – sample 2  
LANE 6, 7& 8 – sample 3 
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(Fig 13) Comparison with Negative Control 
 
 
 
 
 
 
Gradient PCR for CYP1B1 Gene: 
 
 
 
 
 
LANE SAMPLE Conc. ng/μl 
1 Sample 1 305 
2 Sample 2 90.5 
3 Sample 3 147.3 
4 Sample 4 47.4 
5 Sample 5 50 
6 Sample 6 34.8 
7 Sample 7 54.9 
8 Sample 8 61.5 
9 Sample 9 63.6 
10 Sample 10 100.2 
11 Sample 11 52.5 
12 Sample 12 48.9 
LANE 1 – Sample 1  
LANE 2 – NEGATIVE CONTROL FOR sample 1 
LANE 4 – sample 2 
LANE 5 – NEGATIVE CONTROL FOR sample 2  
LANE 7 – sample 3 
LANE 8 – NEGATIVE CONTROL FOR sample 3 
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(Fig 14) Gradient PCR for CYP1B1 Gene 
 
 
 
 
 
 
 
 
As the gene was amplified for varied temperatures, the band that belongs to 57ºC is 
brighter when compared with other temperatures. Due to which 57ºC is chosen as the annealing 
temperature. 
(Fig 15, 16) PCR Amplification of CYP1B1 in three samples 
CYP1B1 amplicon (exon) 786 bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The amplified samples are then gel eluted using Quigenkit and was sequenced. 
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(Fig 17) PCR Amplification of CYP1BI in various clinical samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LANE SAMPLE PRIMER 
1 100 Base pair ladder CYP1B1 
2 Sample 1 CYP1B1 
3 Sample 2 CYP1B1 
4 Sample3 CYP1B1 
5 Sample4 CYP1B1 
6 Sample 5 CYP1B1 
7 Sample 6 CYP1B1 
8 Sample 7 CYP1B1 
9 Sample 8 CYP1B1 
10 Sample 9 CYP1B1 
11 Sample 10 CYP1B1 
12 Sample 11 CYP1B1 
13 Sample 12 CYP1B1 
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Sequence of the CYP1B1 Exon 
 
TCTCCAGAGAGTCAGCTCCGACCTCTCCACCCAACGGCACTCAGTCCCCAGAGGC
TGGGGTAGGGGCGTGGGGCGCCCGCTCCTGTCTCTGCACCCCTGAGTGTCACGCCTT
CTCCTTTCTGTCCCCAGCATGGGCACCAGCCTCAGCCCGAACGACCCTTGGCCGCTA
AACCCGCTGTCCATCCAGCAGACCACGCTCCTGCTACTCCTGTCGGTGCTGGCCACT
GTGCATGTGGGCCAGCGGCTGCTGAGGCAACGGAGGCGGCAGCTCCGGTCCGCGCC
CCCGGGCCCGTTTGCGTGGCCACTGATCGGAAACGCGGCGGCGGTGGGCCAGGCGG
CTCACCTCTCGTTCGCTCGCCTGGCGCGGCGCTACGGCGACGTTTTCCAGATCCGCC
TGGGCAGCTGCCCCATAGTGGTGCTGAATGGCGAGCGCGCCATCCACCAGGCCCTG
GTGCAGCAGGGCTCGGCCTTCGCCGACCGGCCGGCCTTCGCCTCCTTCCGTGTGGTG
TCCGGCGGCCGCAGCATGGCTTTCGGCCACTACTCGGAGCACTGGAAGGTGCAGCG
GCGCGCAGCCCACAGCATGATGCGCAACTTCTTCACGCGCCAGCCGCGCAGCCGCC
AAGTCCTCGAGGGCCACGTGCTGAGCGAGGCGCGCGAGCTGGTGGCGCTGCTGGTG
CGCGGCAGCGCGGACGGCGCCTTCCTCGACCCGAGGCCGCTGACCGTCGTGGCCGT
GGCCAACGTCATGAGTGCCGTGTGTTTCGGCTGCCGCTACAGCCACGACGACCC 
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Multiple sequence alignment using Clustal W2:  
 
Nucleotide sequence of CYP1B1 forward primer 
 
Sample A-CYP F----AGGCTGGGGTAGGGGCGTGGGGCGCCCGCTCCTG 34-  
Sample C- CYP F ---AGGCTGGGGTAGGGGCGTGGGGCGCCCGCTCCTG 36-  
Healthy Sample -----AGGCTGGGGTAGGGGCGTGGGGCGCCCGCTCCTG 50-  
Sample B- CYP F-------GCTGGGGTAGGGGCGTGGGGCGCCCGCTCCTG 32-- 
 
TCTCTGCACCCCTGAGTGTCACGCCTTCTCCTTTCTGTCCCCAGCATGGG 84-  
TCTCTGCACCCCTGAGTGTCACGCCTTCTCCTCTCTGTCCCCAGCATGGG 86-  
TCTCTGCACCCCTGAGTGTCACGCCTTCTCCTTTCTGTCCCCAGCATGGG100-  
TCTCTGCACCCCTGAGTGTCACGCCTTCTCCTTTCTGTCCCCAGCATGGG 82-  
 
GGCCAGCGGCTGCTGAGGCAACGGAGGCGGCAGCTCCGGTCCGCGCCCCC 234-  
GGCCAGCGGCTGCTGAGGCAACGGAGGCGGCAGCTCCGGTCCGCGCCCCC 236-  
GGCCAGCGGCTGCTGAGGCAACGGAGGCGGCAGCTCCGGTCCGCGCCCCC 250-  
GGCCAGCGGCTGCTGAGGCAACGGAGGCGGCAGCTCGGGTCCGCGCCCCC 232-  
 
CATCCACCAGGCCCTGGTGCAGCAGGGCTCGGCCTTCGCCGACCGGCCGG 434-  
CATCCACCAGGCCCTGGTGCAGCAGGGCTCGGCCTTCGCCGACCGGCCGG 436-  
CATCCACCAGGCCCTGGTGCAGCAGGGCTCGGCCTTCGCCGACCGGCCGG 450-  
CATCCACCAGGCCCTGGTGCAGCAGGGCTCGGCCTTCGCCGACCGGCCGT 432-  
 
Common Single Nucleotide Polymorphisms (SNP) are highlighted in red and bold. 
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Protein sequence CYP1B1 Forward primer 
 
Healthy sample –RLGGRGAPAPVSAPLSVTPSPFCPQHGHQPQPE-50  
Sample A_CYP.F -RLGGRGAPAPVSAPLSVTPSPFCPQHGHQPQPE 33  
Sample B_CYP.F-GVGAWGARSCLCT-------PECHAFSFLSPAW 27  
Sample C_CYP.F-RGWGRGVGRPLLSLHPVSRLLLSVPSMGTSLSPN 34-
RPLAAKPAVHPADHAPATPVGAGHCACGPAAAEATEAAAPVRAPGPVCVA 100-  
-RPLAAKPAVHPADHAPATPVGAGHCACGPAAAEATEAAAPVRAPGPVCVA 83-  
-APASARTTLGRTRCPSSRPRSCYSCRCWPLCMWASGCGNGGGSSGPRPRA 77-  
-DPWPLNPLSIQQTTLLLLLSVLATVHVGQRLLRQRRRQLRSAPPGPFAWP 84- 
 
-TDRKRGGGGPGGSPLVRSPGAALRRRFPDPPG--QLPHSGAEWRARHPPG 148  
-TDRKRGGGGPGGSPLVRSPGAALRRRFPDPPG--QLPHSGAEWRARHPPG 131  
-RLRGHSETRRRWARRLTSRSLAWRG-ATATFS--RSAWAAAPWCMASAPS 124  
-LIGNAAAVGQAAHLSFARLARRYGDVFQIRLGSCPIVVLNGERAIHQALV 134 
 
-HAPAAQPPSPRGPRAERGARAGGAAGARQRGRRLPRPEAADRRGRGQRHE 248  
-HAPAAQPPSPRGPRAERGARAGGAAGARQRGRRLPRPEAADRRGRGQRHE 231  
-QPTACATSSRASRAAAKSSRATCARRASWWRCWCAAARTAPSSTRGRPSW 217  
-QPRSRQVLEGHVLSEARELVALLVRGSADGAFLDPRPLTVVAVANVMSAV 234 
 
Common Single Nucleotide Polymorphisms (SNP) are highlighted in red and bold. 
 
Common Single Nucleotide Polymorphisms which are suggestive of published 
CYP1B1 mutations in PCG individuals are found in sample 1 and sample 7 of the patients 
included in this study group. 
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DISCUSSION 
 
 In this study, a detailed clinical evaluation of children presenting with features of 
Congenital Glaucoma was done. 
 Out of the 20 children who were diagnosed to have Primary Congenital Glaucoma before 
the age of 1, 10 % of the children presented with symptoms of PCG within 1 month after 
birth, 65 % of them presented within 1 to 6 months of age and 25 % of them presented 
after 6 months. 90% of the children had bilateral involvement. 
 An analysis of the various symptoms with which patients present in Congenital 
Glaucoma was done. 
 40 % of the children were brought with complaints of Buphthalmos (B) which is marked 
enlargement of eyes, along with photophobia (P) and lacrimation (L). 
 35 % of the children presented with Buphthalmos only. 
 15 % of the children were brought with both Buphthalmos and photophobia. 
 10 % of the children were brought with photophobia and lacrimation, where marked 
enlargement of eyes was either absent or unnoticed by the parents. 
 40 % of the children in the study group had IOP of 21 to 30 mmHg and 40 % had IOP of 
31 to 40 mmHg. 
 15 % of them had IOP above 40 and 5 % had less than 20mm Hg. 
 Only 5 % of the eyes had clear cornea. 62.5 % of eyes had mild haze where fundus could 
still be visualized. 
 32.5% had severe haziness where it was not possible to visualize the fundus. 
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 This is important in the view of surgical management since Goniotomy, which is a 
successful initial line of management, can be performed only in patients who have clear 
cornea to allow adequate visualization of the angle structures. 
 Blood samples were collected from patients diagnosed to have Primary Congenital 
Glaucoma. 
 The study population who attend our tertiary centre represents the south Indian 
population. 
 Genomic DNA was isolated using Qiagen kit. The isolated DNA from the samples were 
checked using agarose gel electrophoresis. 
 We used GAPDH primer at annealing temperature 60oC to confirm the presence and 
quality of genomic DNA. 
 Using the primers exon 2 was amplified by PCR technique and was sequenced. 
 PCR products were then purified with the Qiagen gel/ PCR purification kit, and 
sequenced and analyzed for SNPs.  
 Referral CYP1B1 gene was obtained from GenBank accession number U56438.  
 Multiple Sequence Alignment was done using CLUSTAL W2 to analyse the significance 
of mutations.  
 Then the sequence was analyzed comparing the CYP1B1 gene with the amplified 
products. 
 Presence of Single Nucleotide Polymorphism was identified in two samples. 
 The analysis was done by comparing the sequence of earlier reported exon with the 
amplicon under study obtained by sequencing. 
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 CYP1B1 mutations in PCG individuals suggest the presence of transition mutations that 
was analysed by conceptual translation (Bassem A. Bejjani et al, 1998) 
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CONCLUSION 
 
PCG is one of the common causes of childhood blindness and its genetic etiology has 
been established. Molecular genetics has greatly enhanced our understanding of the molecular 
basis of this disorder. The underlying genes and the pathogenic mutations thereof can be 
identified. 
The technological advances in molecular diagnostics and genetics can aid us to 
characterize pathologic gene changes providing further insight into the molecular pathogenesis 
of these disorders.  In this regard, the incidence of PCG is one in every 10000-15000 live births 
and is bilateral in up to 80% of cases. 
Further, it is interesting to note that most cases are sporadic (90%).  However, in the 
remaining 10% there appears to be a strong familial component. Hence, our study attempted to 
understand the prevalence of PCG in the South Indian population as limited literature is available 
and does not cover data on all the reported PCG gene loci. 
Even though three different loci have been mapped for PCG, mutations in Cytochrome 
P450 (CYP1B1; GLC3A) are the most predominant cause of disease and are reported in various 
ethnic backgrounds. Confirmation of linkage between CYP1B1and PCG in different populations 
have verified the GLC3A locus (CYP1B1) as a major cause of PCG accounting for 85%–90% of 
all familial cases and 27% of sporadic cases. 
Moreover, PCG transmission follows an autosomal-recessive inheritance pattern and has 
both Mendelian and multifactorial genetic-causative traits. 
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Common Single Nucleotide Polymorphisms which are suggestive of published 
CYP1B1 mutations in PCG individuals are found in sample 1 and sample 7 of the patients 
included in this study group. Extensive studies to determine the prevalence of CYP1B1 
mutation in Primary Congenital Glaucoma in India, where there are multiple ethnic groups, are 
yet to be done. Only such large-scale multi-centric studies can establish the prevalence of such 
genetic mutations, and can aid in the development of genetic markers. Hence, the current study 
attempts to show some putative mutations in the population included in it. 
PCG patients and/or their relatives can be given an option for genetic evaluation in order 
to understand the disease well from research point of view as well as help the patient and/ or 
patient’s relatives to take appropriate decisions regarding the disease. Molecular diagnostic 
approaches are likely to improve the diagnostic and management strategies of PCG dramatically 
over the next few decades. 
Genetic testing and molecular diagnostics have many new applications. It helps the 
clinician, patient and his/her family to take further decisions. Genetic testing aids in 
understanding the disorder thereby improving medical care, and the future is foreseen to yield 
continued advances in this direction. In the coming years, genetic counselling will be one of the 
important areas in PCG patient management. 
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PROFORMA 
Name:                
Age:               
Sex: 
IP no: 
Address: 
 
 
Registration Number: 
Contact number: 
Informer: mother/father/relative/others  
Reliability of the Informer: 
 
Presenting complaints: 
 
History of present illness: 
 
Past history: 
H/O treatment for Glaucoma 
H/O Ocular surgery  
Family history: 
H/O similar complaints in the Family 
 
Complaints Duration 
Watering  
Inability to see bright light  
Defective vision  
Increased size of the eye balls  
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Family Pedigree 
 
Marital history: 
(Consanguinity) 
 
Birth history: 
 
GENERAL EXAMINATION: 
Vital data:  
Pulse rate:                            Blood pressure:      
 
SYSTEMIC EXAMINATION:  
 
OCULAR EXAMINATION 
 
Parameters Right eye Left eye 
Visual acuity   
Anterior segment examination with slit lamp   
Corneal diameter   
Fundus examination   
Intra ocular pressure measurement by Icare/Schiotz   
Gonioscopy (if possible)   
  
INVESTIGATIONS: Blood sample for Genetic Analysis 
 
GENETIC ANALYSIS REPORT: 
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54231 6M 2Y F B NIL NIL NIL F + F+ 45 24 
H 14 
V 16 
H12 
V12 
SH MH NV 0.5 
3 
S
A
N
J
A
Y
 
87564 10M 2Y M B,P,L NIL NIL NIL F+ F+ 24 50 
H12 
V11 
H12.5  
V12.5 
MH MH 0.4 0.6 
4 
D
IN
E
S
H
 
32876 3M 1Y M B NIL NIL NIL F+ F+ 34 30 
H12 
V13 
H13 
V13 
MH MH 0.9 0.9 
5 
N
IT
H
Y
A
 
87544 4M 3Y F B,P,L NIL NIL 
2ND 
DEG 
F+ F+ 45 50 
H15 
V14 
H14 
V13 
MH, 
HS 
MH, 
HS 
0.7 0.8 
6 
R
O
S
H
IN
I 
68907 20D 1Y F B,P NIL NIL NIL _ _ 26 29 
H13 
V13 
H14 
V13 
SH SH NV NV 
7 
G
O
U
T
H
A
M
 
34857 8 M 2Y M B NIL NIL NIL F+ F+ 35 24 
H13 
V13 
H14 
V13 
MH, 
HS 
SH 0.7 NV 
8 
D
IN
E
S
H
 
27659 6M 3Y M P,L NIL NIL NIL F+ F+ 26 35 
H11 
V11 
H13 
V13 
CL SH 0.6 NV 
9 
U
D
A
Y
 
90754 2M 1Y M B,P,L NIL NIL 
2ND 
DEG 
F+ F+ 35 40 
H14 
V16 
H14 
V14 
SH SH NV 0.6 
10 
V
IJ
A
Y
A
 
33567 6M 1Y F B,P,L NIL NIL NIL F+ F+ 35 40 
H14 
V14 
H14 
V13 
SH SH NV NV 
11 
S
U
M
IT
H
R
A
 
22470 5D 1Y F B,P NIL NIL NIL _ _ 31 37 
H11 
V11 
H11 
V11 
MH MH NV NV 
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N
A
M
E
 
IN
-P
A
T
IE
N
T
 
N
U
M
B
E
R
 
A
G
E
 
C
U
R
R
E
N
T
 A
G
E
 
S
E
X
 
S
Y
M
P
T
O
M
S
 
S
Y
S
T
E
M
IC
 
IL
L
N
E
S
S
 
F
A
M
IL
Y
 H
IS
T
O
R
Y
 
C
O
N
S
A
N
G
U
IN
IT
Y
 
R
E
 V
n
 A
T
 I
N
IT
IA
L
 
P
R
E
S
E
N
T
A
T
IO
N
 
L
E
 V
n
 A
T
 I
N
IT
IA
L
 
P
R
E
S
E
N
T
A
T
IO
N
 
IO
P
 R
E
 
IO
P
 L
E
 
C
O
R
N
E
A
 
D
IA
M
E
T
E
R
 R
E
 
C
O
R
N
E
A
 
D
IA
M
E
T
E
R
 L
E
 
C
O
R
N
E
A
 R
E
 
C
O
R
N
E
A
 L
E
 
F
U
N
D
U
S
 R
E
 
F
U
N
D
U
S
 L
E
 
12 
S
A
T
H
Y
A
V
A
N
I 
45667 9M 
1 
1/2Y 
F B,P,L NIL NIL NIL F+ F+ 29 20 
H13 
V13 
H10 
V10 
SH CL NV 0.4 
13 
S
H
A
N
K
A
R
I 
88764 3M 10M F B NIL NIL 
2ND 
DEG 
F+ F+ 29 29 
H12.5 
V12 
H12 
V12 
MH, 
HS 
MH, 
HS 
0.5 0.6 
14 
G
A
N
G
A
 
21143 I M 6M F P,L NIL NIL 
2ND 
DEG 
_ _ 26 23 
H11 
V12 
H11 
V11 
MH, 
HS 
MH, 
HS 
0.5 0.5 
15 
R
E
G
IN
A
 
77709 3M 8M F B NIL NIL 
3RD 
DEG 
F+ F+ 29 10 
H14 
V13 
H10 
V10 
SH CLEAR NV 0.4 
16 
S
U
R
IY
A
 
54336 10M 
1 
1/2Y 
M B,P,L NIL NIL NIL F+ F+ 21 45 
H111 
V12 
H12 
V13 
MH, 
HS 
MH, 
HS 
0.6 0.9 
17 
R
A
J
E
S
W
A
R
I 
66812 10M 2Y F B,P NIL NIL NIL F+ F+ 35 29 
H13 
V11 
H12 
V11 
MH 
MH, 
HS 
0.6 0.9 
18 
S
A
A
R
A
T
H
I 
44214 5M 1Y M B NIL NIL NIL 6,36 6,60 30 25 
H12 
V14 
H15 
V14 
MH, 
HS 
MH, 
HS 
0.5 0.7 
19 
M
U
K
IL
A
N
 
77860 2M 4M M B NIL NIL 
3RD 
DEG 
F+ F+ 33 36 
H13 
V13 
H13 
V13 
MH, 
HS 
MH, 
HS 
0.6 0.6 
20 
M
A
N
O
J
 
22123 2M 6M M B,P,L NIL NIL NIL _ _ 32 40 
H14 
V13.5 
H14 
V14 
SH SH NV NV 
 
86 
KEY TO MASTER CHART 
 
Vn- VISION 
 
IOP- INTRAOCULAR   PRESSURE 
 
H- HORIZONTAL 
 
V- VERTICAL 
 
SH- SEVERE HAZE 
 
MH- MILD HAZE 
 
HS- HAAB’S STRIAE 
 
CL- CLEAR 
 
B- BUPHTHALMOS 
 
P- PHOTOPHOBIA 
 
L- LACRIMATION 
 
F+- FIXING THE EYES TO LIGHT 
 
NV- NO VIEW 
 
M- MONTHS 
 
D- DAYS 
 
Y- YEARS 
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ABBREVIATIONS AND SYMBOLS 
PCG- primary congenital glaucoma 
CD ratio- cup disc ratio 
μl- microliter  
bp - Base pairs 
μg- microgram  
DNA - Deoxyribonucleic acid 
mM- millimolar  
ml- millilitre  
mg- milligram 
ng- nanogram  
dNTP - Deoxyribonucleoside triphosphate 
ddNTP - Dideooxynucleoside triphosphate 
rpm- rotation per minute 
EDTA - Ethylene diamine tetra acetic acid 
KCl – Potassium chloride  
kDa - Kilodaltons 
NaCl – Sodium chloride  
PCR - Polymerase chain reaction 
NH4Cl – Ammonium chloride 
RBC - Red blood cell 
HCl – Hydro chloric acid 
SNP – Single nucleotide polymorphism 
EtBr - Ethidium Bromide 
UV – Ultra violet 
